Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States
Authors' conclusion
In this observational, single-cohort study, at 6-month follow-up, patients with T2D initiating tirzepatide showed HbA1c and weight reductions; more pronounced HbA1c reductions occurred in GLP-1 RA naïve patients or those with baseline HbA1c ≥7%, while more weight loss was observed among GLP-1 RA naïve patients or those with baseline HbA1c <7%.
Study context
- Population
- Adults ≥18 years with T2D initiating tirzepatide, US commercially insured population (HIRD®), with ≥1 HbA1c result around index date and end of 6-month follow-up; 58% female, 54 years old, 54% GLP-1 receptor agonist (RA) at baseline, 59% HbA1c ≥7%, 61% overweight/obesity
- Participants
- 2,247 adults
- Outcome
- HbA1c and weight
- Follow-up
- 6-month follow-up
Methodological detailsobservational, single-cohort, pre-post
- Observational
- Single-cohort
- Pre-post
Main finding
As reported in the abstract
HbA1c <7%, overall cohort
69%
Mean change in weight, overall cohort
−6.3 kg
Observational data: associations, not effects.
Further findings
HbA1c <7%, GLP-1 RA naïve subgroup · 6-month follow-up
- HbA1c <7%, GLP-1 RA naïve subgroup
- 77%
Mean change in weight, by subgroup · 6-month follow-up
kg
- Baseline HbA1c <7%
- −7.1
- GLP-1 RA naïve subgroup
- −8.1
Original publication
Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States. Diabetes Obes Metab. Published 4 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →